Reframe Daily: New cancer marker predicts who responds to treatment

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: This week brought hopeful news—from everyday foods helping heart and metabolic health, to smarter cancer treatments, to early signs of a gentler leukemia therapy for patients who need it most.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Personal shares from Christin here →
http://christin.substack.com/

Good news: A randomized trial found both diets based on plant and animal protein were associated with improved in anthropometric indices, MetS components, atherogenic index of plasma, and elevated serum adropin levels.

Does partial replacement of animal protein with plant protein in the diet affect components of metabolic syndrome, adropin levels, and the atherogenic index of plasma? Results from a parallel randomized clinical trial in adults with metabolic syndrome

Market readiness: 🙂🙂🙂🙂🙂 (This is a finished randomized clinical trial; the diet change is something people can adopt now, but broad clinical guideline updates would take more confirmatory work.)

Good news: Researchers found that the presence of plasma cells inside some stomach tumors predicts which patients do better with neoadjuvant immunotherapy — that helps doctors pick the right treatment for more patients.

Intratumoral plasma cells predict patient prognosis and responsiveness to neoadjuvant immunotherapy in advanced gastric cancer

Market readiness: 🙂🙂 (Promising biomarker research that could improve patient selection; not yet a routine clinical test available everywhere.)

Good news: A multicentre phase-2 trial showed that adding G-CSF to venetoclax + azacitidine improved responses in newly diagnosed AML patients who cannot have intensive chemo — offering a better option for a hard-to-treat group.

Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukaemia: a multicentre phase 2 trial

Market readiness: 🙂 (Early-phase clinical trial evidence; larger confirmatory trials and guideline changes are still needed before wide adoption.)

Thank you for taking the time to take care of yourself and your loved ones.